Smykla A, Walewicz K, Trybulski R, Halski T, Kucharzewski M, Kucio C, Mikusek W, Klakla K, Taradaj J
Department of Physiotherapy Basics, Academy of Physical Education in Katowice, Mikolowska 72 Street, 40-065 Katowice, Poland.
Department of Physiotherapy Basics, Academy of Physical Education in Katowice, Mikolowska 72 Street, 40-065 Katowice, Poland ; Department of Medical Biophysics, Medical University of Silesia in Katowice, Medykow 18 Street, 40-752 Katowice, Poland.
Biomed Res Int. 2013;2013:767106. doi: 10.1155/2013/767106. Epub 2013 Nov 27.
The aim of the study was to assess the efficacy of Kinesiology Taping (KT) for treating breast cancer-related lymphedema. Sixty-five women with unilateral stage II and III lymphedema were randomly grouped into the KT group (K-tapes, n = 20), the Quasi KT group (quasi K-tapes, n = 22), or the MCT group (multilayered compression therapy group, n = 23). Skin care, 45 min pneumatic compression therapy, 1 h manual lymphatic drainage, and application of K-tape/Quasi K-tapes/multilayered short-stretch bandages were given every treatment session, 3 times per week for 1 month. Patient evaluation items included limb size and percentage edema. Comparing the changes in K-tapes with quasi K-tapes changes, there were no significant differences (P > 0.05). The edema reduction of multilayered bandages was much better than in results observed in taping groups. The KT appeared to be ineffective at secondary lymphedema after breast cancer treatment. The single-blind, controlled pilot study results suggest that K-tape could not replace the bandage, and at this moment it must not be an alternative choice for the breast cancer-related lymphedema patient. The trial is registered with ACTRN12613001173785.
本研究的目的是评估肌内效贴布（KT）治疗乳腺癌相关淋巴水肿的疗效。65名单侧II期和III期淋巴水肿的女性被随机分为KT组（K贴布，n = 20）、准KT组（准K贴布，n = 22）或MCT组（多层压迫治疗组，n = 23）。每次治疗均进行皮肤护理、45分钟的气压治疗、1小时的手动淋巴引流，并应用K贴布/准K贴布/多层短拉伸绷带，每周3次，共1个月。患者评估项目包括肢体大小和水肿百分比。比较K贴布与准K贴布的变化，差异无统计学意义（P > 0.05）。多层绷带的水肿减轻效果明显优于贴布组。KT在乳腺癌治疗后的继发性淋巴水肿治疗中似乎无效。单盲对照试验研究结果表明，K贴布不能替代绷带，目前它绝不是乳腺癌相关淋巴水肿患者的替代选择。该试验已在澳大利亚临床试验注册中心注册，注册号为ACTRN12613001173785。
